Synpromics announces £5.2M British investment in gene therapy tech

By Flora Southey contact

- Last updated on GMT

image: iStock
image: iStock

Related tags: Dna

Scottish synthetic biology firm Synpromics has received £5.2M ($6.6M) to enhance its synthetic promoter design technology used in gene therapy development.

Funding sources include UK-based companies Calculus Capital, the Scottish Investment Bank, the investment branch of Scottish Enterprise, and private shareholders.

The majority of resources will fund the development of Synpromics’ synthetic promoters – DNA sequences that do not exist in nature – via the company’s PromPT design platform.

PromPT is a bioinformatics database for the design, build and screening of synthetic promoters. The promoters allow for precise control of gene function, impacting gene therapy, cell therapy and gene editing.

Synpromics CEO David Venables described the distinct nature of the PromPT platform late last year​ as a “unique capability for the industrialised development of synthetic promoters which doesn’t exist elsewhere.”

Beginning with a team of nine, Synpromics predicts its increase staff size to increase to up to 35 over the next 12 to 18 months.

The deal follows GE Healthcare’s investment​ in the Scottish company earlier this year.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us

Products

View more

Webinars